NCT01568294View on ClinicalTrials.gov

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 1, 2012

Primary Completion Date

July 8, 2015

Study Completion Date

July 8, 2015

Conditions
Multiple Myeloma
Interventions
DRUG

pomalidomide

2 mg or 4mg oral pomalidomide once per day on Days 1-21 of a 28-day cycle

Trial Locations (8)

467-8602

Nagoya City University Hospital, Nagoya

259-1193

Tokai University Hospital, Isehara

350-8550

Saitama Medical Center, Saitama Medical University, Kawagoe

104-0045

National Cancer Center Hospital, Tyuuou

812-8582

Kyusyu University Hospital, Fukuoka

296-1602

Kameda General Hospital, Kamogawa

951-8566

Niigata Cancer Center Hospital, Niigata

701-1192

Okayama Medical Center, Okayama

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT01568294 - Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter